	US 12,233,185 B2
	Microfluidic extrusion
Michael P. Francis, Norfolk, VA (US); Stella Petrova, Blacksburg, VA (US); and Nicholas Thayer, Morrisville, NC (US)
Assigned to Embody, Inc., Norfolk, VA (US)
Filed by Embody, Inc., Norfolk, VA (US)
Filed on Apr. 23, 2021, as Appl. No. 17/239,013.
Application 17/239,013 is a continuation of application No. 16/779,196, filed on Jan. 31, 2020, granted, now 11,020,509.
Claims priority of provisional application 62/800,317, filed on Feb. 1, 2019.
Prior Publication US 2021/0252190 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61L 27/24 (2006.01); A61L 17/10 (2006.01); A61L 17/14 (2006.01); A61L 27/38 (2006.01); D01D 5/02 (2006.01); D01D 5/06 (2006.01); D01D 5/38 (2006.01); D01D 7/00 (2006.01); D01F 4/00 (2006.01)

CPC A61L 27/24 (2013.01) [A61L 17/105 (2013.01); A61L 17/14 (2013.01); A61L 27/3804 (2013.01); A61L 27/386 (2013.01); D01D 5/02 (2013.01); D01D 5/06 (2013.01); D01D 5/38 (2013.01); D01D 7/00 (2013.01); D01F 4/00 (2013.01); A61L 2430/10 (2013.01)]

18 Claims

1. An extruded collagen fiber, wherein the extruded collagen fiber has the following characteristics:

an ultimate tensile strength of between about 20 MPa to about 1,700 MPa;

a modulus of elasticity of between about 200 MPa to about 20,000 MPa;

a strain at break of between about 2 percent and about 45 percent elongation;

an average fiber diameter between about 10 μm and less than about 200 μm;

maintains its strength after soaking in Dulbecco's Phosphate Buffered Solution (“DPBS”) at room temperature for about 1 hour; and

promotes an elevated pro-regenerative M2 macrophage response in vivo, wherein the fiber further comprises sub-fibers that are cross-linked with glyoxal.